Therapeutic options in a patient with MELAS and diabetes mellitus: follow-up after 6 months of treatment

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Yatsuga S et al (2012) MELAS: a nationwide prospective cohort study of 96 patients in Japan. Biochim Biophys Acta 1820(5):619–624

    CAS  Article  Google Scholar 

  2. 2.

    Divakaruni SA et al (2013) Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci USA 110(14):5422–7

    CAS  Article  Google Scholar 

  3. 3.

    El-Hattab AW et al (2014) Glucose metabolism derangements in adults with the MELAS m.3243A > G mutation. Mitochondrion 18:63–69

    CAS  Article  Google Scholar 

  4. 4.

    Maedler K et al (2005) Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90:501–506

    CAS  Article  Google Scholar 

  5. 5.

    Artuso R et al (2015 Feb) Therapeutic implications of novel mutations of the RFX6 gene associated with early-onset diabetes. Pharmacogenomics J 15(1):49–54

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to C. Cosentino.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the patient included in the study.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Managed by Massimo Federici.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cosentino, C., Contento, M., Paganini, M. et al. Therapeutic options in a patient with MELAS and diabetes mellitus: follow-up after 6 months of treatment. Acta Diabetol 56, 1231–1233 (2019). https://doi.org/10.1007/s00592-019-01302-z

Download citation

Keywords

  • MELAS
  • Diabetes
  • DPPIV inhibitors